Clinical trial
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
NCT00093015 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00093015 |
|---|---|
| Title | Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) |
| Official title | Trial to Reduce Cardiovascular Events With Aranesp® Therapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Disease, Diabetes Mellitus, Anemia |
| Intervention type | Drug |
| Interventions | Placebo, darbepoetin alfa |
| Enrollment | 4,038 |
| Start date | Aug 1, 2004 |
| Primary completion | Mar 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Sep 29, 2004 |
| Last update posted | Nov 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: